Bispecific antibody therapy

Request an Appointment
Print

Mayo Clinic's approach

Mayo Clinic has a unique, seamless outpatient-inpatient setup for bispecific antibody therapy and cellular therapy. This setup makes it easier for people to receive the right level of care based on their current needs. Mayo has a specialized team of doctors and staff with extensive experience taking care of people receiving these therapies. Mayo Clinic is leading innovative ways of bispecific antibody therapy delivery, such as rapid step-up dosing.

Access to the latest treatments

Mayo Clinic doctors have access to the latest biological treatments approved for people with cancer, including bispecific antibody therapy and CAR-T cell therapy. Your cancer treatment plan takes into account the most up-to-date information.

Researchers also are actively involved in clinical trials that examine different combinations of bispecifics for cancer and other diseases, such as hemophilia. These research studies offer participants earlier access to new treatments and may be the first choice for patients without other treatment options.

Expertise and rankings

Mayo Clinic doctors are nationally recognized for their experience with biological therapies for complex and serious illnesses. Mayo Clinic Comprehensive Cancer Center is designated by the National Cancer Institute for its scientific excellence and team-based approach to cancer care.

Mayo Clinic in Rochester, Minnesota, Mayo Clinic in Jacksonville, Florida, and Mayo Clinic in Phoenix/Scottsdale, Arizona, are ranked among the Best Hospitals for cancer by U.S. News & World Report.

Locations, travel and lodging

Mayo Clinic has major campuses in Phoenix and Scottsdale, Arizona; Jacksonville, Florida; and Rochester, Minnesota. The Mayo Clinic Health System has dozens of locations in several states.

For more information on visiting Mayo Clinic, choose your location below:

Mayo Clinic's campus in Arizona

Mayo Clinic's campus in Florida

Mayo Clinic's campus in Minnesota

Mayo Clinic Health System

Mayo Clinic Healthcare, located in London

Costs and insurance

Mayo Clinic works with hundreds of insurance companies and is an in-network provider for millions of people.

In most cases, Mayo Clinic doesn't require a physician referral. Some insurers require referrals or may have additional requirements for certain medical care. All appointments are prioritized on the basis of medical need.

Learn more about appointments at Mayo Clinic.

Please contact your insurance company to verify medical coverage and to obtain any needed authorization prior to your visit. Often, your insurer's customer service number is printed on the back of your insurance card.

More information about billing and insurance:

Mayo Clinic in Arizona, Florida and Minnesota

Mayo Clinic Health System

By Mayo Clinic Staff
Request an appointment
Doctors & Departments
Jan. 24, 2026
Print
  1. Klein C, et al. The present and future of bispecific antibodies for cancer therapy. Nature Reviews Drug Discovery. 2024; doi:10.1038/s41573-024-00896-6.
  2. Manis JP. Overview of therapeutic monoclonal antibodies. https://www.uptodate.com/contents/search. Accessed Sept. 30, 2025.
  3. Guidi L, et al. Bispecific antibodies in hematologic and solid tumors: Current landscape and therapeutic advances. American Society of Clinical Oncology Educational Book. 2025; doi:10.1200/EDBK-25-473148.
  4. Gu Y, et al. Clinical progresses and challenges of bispecific antibodies for the treatment of solid tumors. Molecular Diagnosis & Therapy. 2024; doi:10.1007/s40291-024-00734-w.
  5. Verma V, et al. Bispecific antibodies in clinical practice: Understanding recent advances and current place in cancer treatment landscape. Clinical and Experimental Medicine. 2025; doi:10.1007/s10238-024-01520-y.
  6. Jain MD, et al. Easy as ABC: Managing toxicities of antibody-drug conjugates, bispecific antibodies, and CAR T-cell therapies. ASCO Educational Book. 2025; doi:10.1200/EDBK-25-473916.
  7. Tan CR, et al. Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): An International Myeloma Working Group study. Blood Cancer Journal. 2025; doi:10.1038/s41408-025-01259-z.
  8. Choi SM, et al. Mechanism of action and pharmacokinetics of approved bispecific antibodies. Biomolecules & Therapeutics. 2024; doi:10.4062/biomolther.2024.146.
  9. Medical review (expert opinion). Mayo Clinic. Sept. 30, 2025.
  10. Tecvayli (prescribing information). Janssen Biotech; 2022 https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TECVAYLI-pi.pdf. Accessed Sept. 29, 2025.
  11. Imdelltra (prescribing information). Amgen; 2024. https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/Imdelltra/imdelltra_fpi.pdf. Accessed Oct. 1, 2025.
  12. Raje N, et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: Consensus recommendations from an expert panel. Blood Cancer Journal. 2023; doi:10.1038/s41408-023-00879-7.
  13. Britto J, et al. Bispecific antibody toxicities. CMAJ. 2025; doi:10.1503/cmaj.241384.
  14. Morris EC, et al. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nature Reviews Immunology. 2022; doi:10.1038/s41577-021-00547-6.
  15. Derman B, et al. Real-world evidence evaluating teclistamab in patients with relapsed/refractory multiple myeloma: A systematic literature review. Cancers. 2025; doi:10.3390/cancers17071235.
  16. Health Education & Content Services. Staying connected with remote patient monitoring. Mayo Clinic; 2022.
  17. Altered immunocompetence. Centers for Disease Control and Prevention. https://www.cdc.gov/vaccines/hcp/imz-best-practices/altered-immunocompetence.html. Accessed Nov. 14, 2025.
  18. Rybrevant (prescribing information). Janssen Biotech; 2021. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  19. Blincyto (prescribing information). Amgen; 2014. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  20. Elrexfio (prescribing information). Pfizer; 2023. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  21. Hemlibra (prescribing information). Genentech; 2017. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  22. Epkinly (prescribing information). Genmab US; 2023. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  23. Vabysmo (prescribing information). Genentech; 2023. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  24. Lunsumio (prescribing information). Genentech; 2022. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  25. Kimmtrak (prescribing information). Immunocore; 2022. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  26. Haydu E, et al. The rules of T-cell engagement: Current state of CAR T cells and bispecific antibodies in B-cell lymphomas. Blood Advances. 2024; doi.org/10.1182/bloodadvances.2021004535.
  27. Columvi (prescribing information). Genentech; 2023. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 20, 2025.
  28. Talvey (prescribing information). Janssen Biotech; 2023. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 26, 2025.

Related

Bispecific antibody therapy